~~<i id='25A2BB296C'><strike id='25A2BB296C'><tt id='25A2BB296C'><pre id='25A2BB296C'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：leisure time 2025-10-02 01:33:41 Page View：57

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sage's campaign to raise awareness of postpartum depression hits a nerve
Next article： What does generative AI mean for health care? We asked experts

focus

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

Sage's campaign to raise awareness of postpartum depression hits a nerve

Thecampaignfeatureswomenwithpacifiersintheirmouthsandtheslogan"SilenceSucks."SageTherapeuticsSageThe

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

0:58FormerPresidentDonaldTrumppausesforcheersfromthecrowdbeforespeakingasthekeynotespeakeratthe56thA